Speaker(s): 

Phillip Croce, DO - Internal Medicine Resident PGY-3 - Geisinger Health System - has nothing to disclose.

Moderator(s): 

Connor Dougherty, DO, Staff Member, Geisinger - has nothing to disclose. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Review the History of AML
  • Discuss Acute Myeloid Leukemia and recognize its clinical significance, epidemiology and pathophysiology throughout history.
• Identify Clinical Presentation and Diagnosis
  • Recognize common symptoms and physical exam findings in patients with AML and discuss the diagnostic criteria.
• Differentiate Classifications
  • Explain the FAB and WHO classifications of AML and how risk stratification impacts treatment decisions.
• Review Treatment Strategies
  • Summarize the current treatment options for AML, including induction and consolidation therapies, as well as emerging targeted therapies.
• Recognize Advances in Research
  • Identify recent advances in AML treatment, including immunotherapy and personalized medicine approaches.

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Conner Dougherty, DO; Karlyn Paglia, MD; Juan R. Escobar, MD; Shashank Kotakonda, MD; Jayalakshmi Nair, MD; Jignesh Patel, MD; Jameson Woodard, MD; Hasan Zerti, MD and Eric Drago, MD have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPPA compliant.